B12 Beyond the Basics: Cellular Resistance and Functional Deficiencies

B12 Beyond the Basics: Pernicious Anemia, Cellular Resistance, and Functional Deficiencies

Introduction

Vitamin B12 is essential to DNA synthesis, red blood cell formation, neurological integrity, and methylation — the process by which the body converts homocysteine to methionine. Deficiency at any of these levels can produce serious and, if uncorrected, permanent damage: megaloblastic anemia, peripheral neuropathy, spinal cord degeneration, cognitive impairment, and psychiatric symptoms that are frequently misattributed to primary mental illness.

The problem facing both patients and clinicians is that B12-related illness is not a single condition with a single cause. Pernicious anemia (PA) — the best-known cause of B12 deficiency — results from an autoimmune failure of absorption. But a growing body of evidence describes a different category of B12-related illness in which absorption is intact and blood B12 levels appear normal, yet symptoms of deficiency persist. This second category, sometimes called B12 resistance or cellular resistance, reflects failures in transport, cellular uptake, or intracellular conversion after B12 has entered the bloodstream.

Understanding the distinction between these two categories matters clinically. Treatment that works for one may be insufficient or misdirected for the other. This guide explains both conditions, the laboratory and clinical tools available to distinguish them, the treatment approaches supported by evidence, and the neurological stakes of delayed or inadequate care.

For comprehensive detail on PA symptoms, progression, and neurological prevention protocols, this guide should be read alongside the companion clinical document at dittany.com/preventing-neurological-damage/.

What It Is

Pernicious anemia is an autoimmune disorder in which the immune system attacks either intrinsic factor (IF) — the protein produced by gastric parietal cells that binds B12 in the duodenum and enables its absorption — or the parietal cells themselves. Without functional intrinsic factor, B12 cannot be absorbed through the normal intestinal pathway regardless of dietary intake. The result is progressive B12 depletion that, without treatment, causes irreversible neurological damage.

The name is misleading. Anemia, though common, is neither the first nor the most consequential feature of the disease. Neuropsychiatric symptoms — depression, anxiety, paresthesia, gait disturbances, cognitive impairment — frequently appear before any hematological abnormality. In approximately 25–30% of PA cases, neurological damage occurs without anemia or macrocytosis at all. The implication is significant: waiting for anemia to appear before treating is waiting too long.

Without adequate treatment, patients will develop permanent spinal cord damage (subacute combined degeneration), irreversible peripheral neuropathy, permanent cognitive impairment, and progressive disability. Neurological recovery, when it occurs, is slower than hematological recovery and is inversely proportional to the severity and duration of untreated deficiency. Early diagnosis and aggressive treatment are not optional — delayed treatment guarantees worse outcomes.

Diagnosis

PA diagnosis involves a combination of laboratory testing and clinical assessment. No single test is definitive, and the clinical picture carries significant weight.

Antibody Testing

Intrinsic factor antibodies are highly specific for PA — specificity approaches 100% — but sensitivity is only 40–60%. This means that up to 60% of patients with confirmed PA will test negative. A negative result does not rule out the diagnosis. Two antibody subtypes exist: Type 1 (blocking antibodies) prevent B12 from binding to intrinsic factor; Type 2 (binding antibodies) prevent the B12–IF complex from attaching to intestinal receptors.

Parietal cell antibodies are present in approximately 90% of PA patients but are considerably less specific, appearing in roughly 10% of the general population. They are useful as supporting evidence, not confirmation.

Functional Markers

Serum B12, holotranscobalamin (active B12), methylmalonic acid (MMA), and homocysteine each measure something different, and each has limitations.

Serum B12 measures all circulating B12, including biologically inactive forms. It is a crude marker — falsely normal in liver disease, kidney disease, and malignancy, and falsely elevated after recent supplementation while functional deficiency persists at the cellular level. Normal serum B12 has been documented in patients with severe neurological symptoms.

Holotranscobalamin (active B12) measures the fraction of B12 bound to transcobalamin and actually delivered to cells. It is more sensitive than total serum B12 for early deficiency but still reflects blood transport rather than intracellular function. In malabsorption states, transport may appear adequate while cellular utilization — particularly in nervous tissue — has already failed.

Methylmalonic acid (MMA) rises when B12-dependent intracellular enzymes are impaired and is the best available laboratory marker of functional deficiency. It is still imperfect: MMA can be normal despite cellular deficiency, and more than half of individuals with low holotranscobalamin have normal MMA. Patients with normal MMA, homocysteine, and serum B12 have nonetheless responded clinically to B12 treatment.

Homocysteine is elevated in B12 deficiency but is less specific than MMA. It also rises in folate deficiency, kidney disease, and hypothyroidism.

Core Diagnostic Principle: No blood test can reliably determine whether nervous system tissue has adequate B12, particularly in malabsorption disorders. Normal or elevated laboratory values do not exclude functional deficiency. Clinical symptoms should guide diagnosis rather than isolated laboratory values. When clinical suspicion is high, empirical treatment should not be delayed — clinical response to B12 therapy can itself confirm the diagnosis.

Treatment

The standard treatment for PA is lifelong B12 injections that bypass the failed absorption pathway entirely. Treatment protocols should be guided by clinical response, not laboratory values.

Initial Phase

With neurological involvement: 1000 mcg intramuscularly or subcutaneously on alternate days until no further improvement, then adjusted to maintain that improvement.

Without neurological involvement: 1000 mcg intramuscularly or subcutaneously three times per week for two weeks, then adjusted to maintain symptom control.

Maintenance

Standard guidelines suggest B12 every one to three months, but this is a starting point, not a fixed ceiling. Many patients require more frequent dosing. No maximum injection frequency exists. The correct frequency is the one that prevents symptom recurrence — determined by clinical assessment, not laboratory values.

If symptoms return before the next scheduled injection, that is clinical evidence of inadequate dosing frequency. Patients who report improvement after injection followed by gradual symptom return, shortening symptom-free intervals, or functional decline before their next dose are not describing a subjective complaint — they are describing undertreated PA.

Common Treatment Errors

• Using serum B12 or other laboratory values to determine injection frequency. Blood markers can normalize while cellular deficiency persists and tissue repair continues.
• Inadequate loading doses. Standard monthly injections are insufficient as initial treatment.
• Reducing injection frequency as soon as the patient feels better or labs normalize.
• Dismissing symptom recurrence between injections.
• Supplementing folic acid without documented folate deficiency — folate can mask anemia while neurological damage progresses.

A note on oral B12: Some studies report that very high-dose oral B12 (1,000–2,000 mcg daily) can normalize serum B12 and metabolic markers through passive diffusion in PA patients. These studies have significant limitations: small sample sizes, short follow-up, and outcomes measured in blood rather than at the intracellular or neurological level. Blood markers can normalize while cellular deficiency persists. Intramuscular or subcutaneous administration remains the recommended route, particularly for patients with neurological involvement and during initial treatment phases.

Monitoring and Associated Risks

Routine laboratory monitoring is not required for patients on regular parenteral B12. Treatment frequency should be adjusted based on symptom control. A lack of clinical improvement after four to eight weeks for hematological symptoms, or six to twelve months for neurological symptoms, suggests either that the diagnosis is incorrect or that dose or route requires adjustment.

PA carries meaningful long-term risks beyond B12 deficiency itself. Patients have a two- to three-fold increased risk of gastric adenocarcinoma and an eleven-fold increased risk of gastric carcinoid tumors. European guidelines recommend initial endoscopy with topographical biopsies and surveillance endoscopy every three to five years for patients with advanced atrophy. Up to 50% of PA patients develop concurrent iron deficiency — achlorhydria impairs dietary iron absorption — and annual iron panels (ferritin, iron, TIBC) are warranted. PA is also associated with other autoimmune conditions: thyroid disease in approximately 40% of patients, type 1 diabetes in approximately 10%, and a range of other autoimmune disorders. Screening should be guided by the patient’s clinical picture.

The Problem Serum B12 Cannot Detect

B12 resistance describes a set of conditions in which symptoms of deficiency persist despite normal or elevated serum B12. The problem is not absorption — these patients have adequate B12 in the bloodstream — but in the steps that follow: binding to transcobalamin II (TCII), receptor-mediated uptake into cells via the transcobalamin receptor CD320, and conversion to the active forms methylcobalamin and adenosylcobalamin that enzymes actually require.

These are not rare theoretical mechanisms. Genetic mutations in key transport genes, autoimmune attacks on receptors, and metabolic disruptions from medications such as metformin and proton pump inhibitors can all impair these downstream steps. The clinical signature is consistent: symptoms of B12 deficiency, normal blood tests, and inadequate response to standard supplementation.

Autoimmune B12 Central Deficiency: The Anti-CD320 Mechanism

A 2024 study published in Science Translational Medicine by Pluvinage et al. identified a specific autoimmune mechanism that produces B12 deficiency isolated to the central nervous system. [Pluvinage et al., Science Translational Medicine, 2024; DOI: 10.1126/scitranslmed.adl3758]

The transcobalamin receptor CD320 is the primary entry point for B12 into cells. It is particularly concentrated in the endothelial cells of the blood-brain barrier (BBB), where it mediates transport of holotranscobalamin into the cerebrospinal fluid (CSF). The researchers identified an autoantibody — anti-CD320 — that blocks this receptor, depleting it from the cell surface and preventing B12 from crossing the BBB.

The result is a distinctive pattern: normal serum B12, near-undetectable CSF B12, and neurological symptoms without any hematological signs of deficiency. The reason hematopoietic cells are spared involves a separate finding from the same study: a genome-wide CRISPR screen identified the low-density lipoprotein receptor (LDLR) as an alternative B12 uptake pathway in blood cells. Because blood cells can use LDLR when CD320 is blocked, they remain B12-sufficient even when the brain is not.

The index case in the study — a 67-year-old woman with systemic lupus erythematosus — presented with progressive tremor, ataxia, and scanning speech. Her serum B12 ranged from 614 to 1,162 pg/mL throughout her illness (well within normal range), while her CSF B12 was 1.6 pg/mL, compared to a mean of 9.0 pg/mL in healthy controls. Anti-CD320 autoantibodies were identified using phage immunoprecipitation sequencing (PhIP-seq). After immunosuppression and high-dose oral B12 supplementation, her CSF B12 rose and she showed gradual clinical improvement over three years — regaining legible handwriting, intelligible speech, and the ability to play the piano.

In a cohort of 28 patients with neuropsychiatric SLE (NPSLE), anti-CD320 autoantibodies were present in 21.4%, compared to 5.6% in non-neurologic SLE patients — an odds ratio of 3.97. The study also found anti-CD320 in 6% of healthy controls, though the clinical relevance of that finding in asymptomatic individuals is not yet established and will require larger prospective studies.

The diagnostic specificity of anti-CD320 seropositivity for predicting a low CSF-to-serum holotranscobalamin ratio was 96%, with 36% sensitivity. Detection in serum also predicted elevated CSF MMA — a metabolic marker of B12 deficiency — with a 78% positive predictive value. These figures come from 132 paired serum and CSF samples, primarily from patients with multiple sclerosis or other neurological diseases.

What the Pluvinage study established — and what remains open: The study confirmed that anti-CD320 is a functional autoantibody capable of blocking B12 transport across the blood-brain barrier and producing CSF B12 deficiency despite normal blood levels. What it could not establish — and the authors are explicit about this — is whether anti-CD320 primarily drives disease, acts as a secondary factor, or in some cases passively spectates. Prospective studies with empirical treatment of seropositive patients are needed to answer that question.

Genetic Forms of B12 Resistance

Inherited defects in B12 transport and metabolism produce resistance at the cellular level and can present at any age, though early-onset forms typically appear in infancy.

Transcobalamin II (TCII) deficiency results from mutations in the TCN2 gene, which encodes the primary B12 transport protein in the bloodstream. Without functional TCII, holotranscobalamin cannot be formed and B12 cannot be delivered to cells via the CD320 receptor. Serum B12 may appear normal while MMA and homocysteine are elevated, and hematological and neurological deficits develop. Treatment typically involves frequent hydroxocobalamin injections with cofactor support. Two representative cases from the published literature illustrate the condition:

• A 2.2-month-old girl presented with diarrhea, fever, poor feeding, pancytopenia, and malnutrition. Serum B12 was 275.60 pmol/L (normal), but urine MMA was elevated at 23.87 μmol/L and homocysteine at 21.85 μmol/L. Compound-heterozygous TCN2 mutations were identified. Intramuscular hydroxocobalamin twice weekly resolved symptoms; normal development was documented at age two years and seven months. [Luo et al., Frontiers in Genetics, 2022]
• A 2-month-old girl presented with failure to thrive, irritability, diarrhea, pallor, and pancytopenia. Serum B12 was normal (351 pg/mL); homocysteine was elevated at 40 μmol/L. A homozygous TCN2 deletion was identified. Daily hydroxocobalamin plus folic acid resolved symptoms; she remained asymptomatic at age four. [Ünal et al., Turkish Journal of Haematology, 2015]

Cobalamin C (cblC) deficiency results from mutations in MMACHC, a gene involved in intracellular B12 processing. It is the most common inherited disorder of B12 metabolism. Early-onset forms present in infancy with severe metabolic crisis; late-onset forms may not appear until adolescence or adulthood and are frequently misdiagnosed. Two late-onset cases from the literature:

• A 16-year-old girl presented with depression that progressed to gait disturbance and limb weakness. Elevated MMA and homocysteine led to genetic testing; compound-heterozygous MMACHC mutations were identified. B vitamin supplementation improved symptoms. [Cheng et al., Frontiers in Genetics, 2022]
• A 30-year-old man presented with unsteady walking, ataxia, and cognitive impairment. Elevated propionylcarnitine and MMA prompted genetic testing; compound-heterozygous MMACHC mutations were confirmed. Treatment with intramuscular methylcobalamin plus betaine, folate, and carnitine improved gait, cognition, and laboratory markers within one month. [Sun et al., Frontiers in Neurology, 2023]

The key differences between pernicious anemia and B12 resistance are summarized below. In practice, the distinction rests on the combination of clinical presentation, response to standard treatment, and selective advanced testing when standard treatment fails.

The most important clinical signal is treatment response. A patient with PA who is treated adequately — correct dosing, correct route, correct frequency — should show hematological improvement within five to seven days and neurological improvement over months. If symptoms persist despite normalized blood B12 and appropriate dosing, resistance mechanisms warrant investigation.

Before concluding that resistance is present, other mimics should be excluded: copper deficiency, thyroid dysfunction, and folate deficiency can produce overlapping presentations. These are more common than genetic B12 transport defects and should be ruled out first.

Standard Testing

Initial evaluation should include serum B12, holotranscobalamin, MMA, homocysteine, and — when PA is suspected — intrinsic factor and parietal cell antibodies. A complete blood count with peripheral smear (looking for macrocytosis and hypersegmented neutrophils) and a thorough symptom history remain central to diagnosis.

As discussed in Section 1, normal values on any of these tests do not exclude deficiency. MMA is the most sensitive functional marker, but even it can be normal while cellular deficiency persists. The hierarchy of reliability runs: MMA, then holotranscobalamin, then serum B12, then homocysteine. None is definitive.

Advanced and Emerging Testing

When standard treatment fails and the clinical picture remains consistent with B12-related illness, advanced testing can identify specific resistance mechanisms.

• CSF B12 and MMA: In cases with neurological focus and normal blood B12, lumbar puncture for CSF B12 and MMA can reveal CNS-specific deficiency invisible to blood tests. Low CSF B12 with elevated CSF MMA, in the context of normal serum values, points toward a blood-brain barrier transport defect.
• Anti-CD320 antibody assay: Phage immunoprecipitation sequencing (PhIP-seq) can detect anti-CD320 autoantibodies. In the Pluvinage et al. study, seropositivity predicted a low CSF/serum holotranscobalamin ratio with 96% specificity. This test is not yet standard clinical practice but is available in research and specialized settings.
• Genetic panels: TCN2 (for TCII deficiency) and MMACHC (for cobalamin C defects) sequencing is appropriate when metabolic markers are elevated and the clinical picture fits, particularly in pediatric patients or those with a family history of metabolic disease.
• Persistent functional markers: Homocysteine and MMA that remain elevated after supplementation — with cofactor interference from folate and B6 excluded — suggest ongoing intracellular deficiency regardless of serum B12 levels.

Diagnostic Sequence

A practical sequence for evaluating suspected B12-related illness:

1. Symptoms plus low serum B12: test for PA with intrinsic factor and parietal cell antibodies. If positive, treat. If negative with high clinical suspicion, treat empirically — a negative antibody test does not exclude PA.
2. Normal or high serum B12 plus persistent symptoms: measure MMA and homocysteine. If elevated, proceed to advanced evaluation based on the symptom profile.
3. Neurological focus with normal blood markers: consider CSF analysis for B12 and MMA, and anti-CD320 antibody testing.
4. Hematological or metabolic abnormalities in pediatric patients or those with family history: pursue genetic screening for TCN2 and MMACHC.
5. When labs are normal but clinical suspicion is high: empirical B12 treatment is appropriate. Clinical improvement with treatment is itself diagnostic evidence.

Pernicious Anemia

Treatment protocols are covered in Section 1. The essential principles: injections to bypass absorption, guided by clinical response rather than lab values, with frequency individualized to the patient and adjusted if symptoms recur between doses.

B12 Resistance

Treatment for resistance depends on the underlying mechanism.

For autoimmune resistance (anti-CD320): The goal is to both reduce autoantibody production and increase CSF B12 by saturation. In the Pluvinage et al. cases, immunosuppression (corticosteroids, hydroxychloroquine, rituximab in one case) combined with high-dose oral B12 supplementation was associated with increased CSF B12 and clinical improvement. Case 8 in the study — who presented with classic spinal cord degeneration findings — showed MRI resolution after B-cell depletion therapy and high-dose oral B12. Whether immunosuppression worked by dampening alternative neuroinflammatory mechanisms or by reducing anti-CD320 production could not be determined from the available data.

For TCII deficiency: Frequent intramuscular hydroxocobalamin — typically twice weekly initially — to saturate alternative uptake pathways, combined with betaine, folate, and carnitine to address elevated homocysteine and MMA. Monitoring of functional markers guides dose adjustment.

For cobalamin C (cblC) deficiency: Intramuscular methylcobalamin combined with betaine, folate, and carnitine. The late-onset case by Sun et al. showed improvement in gait, cognition, and laboratory markers within one month of treatment. Earlier diagnosis generally produces better outcomes; late-onset forms are frequently missed for months to years.

General Principles Across Both Categories

• Cofactors matter. Folate and B6 are required for the methylation cycle that B12 supports. Deficiencies in either can blunt response to B12 treatment. They should be measured and corrected, not assumed.
• Never supplement folic acid alone in suspected B12 deficiency. Folate can mask anemia while neurological damage progresses unchecked.
• Dietary sources of B12 (animal products) support treatment but cannot substitute for injection in PA or in conditions where cellular uptake is impaired.
• Sublingual and high-dose oral methylcobalamin may offer incremental benefit for some patients as adjuncts, but the evidence base is limited and they should not replace injectable treatment in neurologically affected patients.

The central clinical insight this guide builds toward is straightforward: B12-related illness encompasses at least two distinct categories of pathology, and distinguishing them changes treatment. Pernicious anemia is a failure of absorption — B12 never reaches the bloodstream in adequate amounts, serum levels are low, and the fix is bypassing the gut entirely with injections. B12 resistance is a failure downstream — absorption is intact, blood levels look normal or even high, but B12 cannot reach the cells that need it, particularly in the brain.

This distinction has direct implications for diagnosis. A patient with classic PA symptoms and low serum B12 needs antibody testing and, regardless of those results, empirical treatment if clinical suspicion is high. A patient with persistent neurological symptoms and normal blood B12 needs a different investigation — MMA and homocysteine to start, CSF analysis and advanced antibody testing if those are unrevealing. In both cases, normal laboratory values are not a finding that rules out disease. They are a finding that requires clinical interpretation.

The neurological stakes make this interpretation urgent. Neurological damage from B12 deficiency can precede anemia, can occur without it entirely, and can become permanent if treatment is delayed or inadequate. The degree of recovery is directly related to how quickly and aggressively treatment begins.

The Pluvinage et al. findings on anti-CD320 autoantibodies add a specific mechanism to what was previously a poorly characterized category of treatment-resistant B12 illness. CNS-specific B12 deficiency — normal blood levels, near-absent CSF B12, neurological deterioration — now has a testable autoimmune explanation in at least a subset of patients, and early evidence that it responds to immunosuppression combined with high-dose B12. Larger prospective studies are needed to establish prevalence, define which patients benefit from testing, and determine optimal treatment protocols.

What the current evidence supports clearly is the value of not stopping at a normal serum B12 level when the clinical picture says otherwise.

Primary Sources

Pluvinage JV, Ngo T, Fouassier C, et al. Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency. Science Translational Medicine. 2024;16(753):eadl3758. https://doi.org/10.1126/scitranslmed.adl3758

Luo J, Yang X, Liu H, Li Z, Li Y. Case report: Novel compound-heterozygous mutations in the TCN2 gene identified in a Chinese girl with transcobalamin deficiency. Frontiers in Genetics. 2022;13:951007. https://doi.org/10.3389/fgene.2022.951007

Ünal Ş, Rupar T, Yetgin S, et al. Transcobalamin II deficiency in four cases with novel mutations. Turkish Journal of Haematology. 2015;32(4):317–322. https://doi.org/10.4274/tjh.2014.0100

Cheng S, Zhang X, Li X. Case report: A late-onset cobalamin C defect first presenting as a depression in a teenager. Frontiers in Genetics. 2022;13:1024567. https://doi.org/10.3389/fgene.2022.1024567

Sun M, Lu Y, Wu X, et al. Late-onset cobalamin C deficiency type in adult with cognitive and behavioral disturbances and significant cortical atrophy and cerebellar damage in the MRI: A case report. Frontiers in Neurology. 2023;14:1292545. https://doi.org/10.3389/fneur.2023.1292545

Companion Clinical Resource

Pernicious Anemia: Recognizing and Preventing Irreversible Neurological Damage — Quick Reference for Physicians. dittany.com/preventing-neurological-damage/

Further Reading

Stabler SP. Vitamin B12 deficiency. New England Journal of Medicine. 2013;368:149–160.

Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nature Reviews Disease Primers. 2017;3:17040.

Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. New England Journal of Medicine. 1988;318:1720–1728.

Nielsen MJ, Rasmussen MR, Andersen CBF, Nexø E, Moestrup SK. Vitamin B12 transport from food to the body’s cells — a sophisticated, multistep pathway. Nature Reviews Gastroenterology and Hepatology. 2012;9:345–354.